A factor VIIIa–mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice - ScienceDirect
A Novel Next-Generation FVIII Mimetic, Mim8, Has a Favourable Safety Profile. Results from a 26-Week Safety Study in Cynomolgus Monkeys - ScienceDirect
Novo Nordisk's hemophilia drug shows potential as once-monthly treatment — MedWatch
Novo Nordisk to buyout Emisphere Technologies for $1.8B (NYSE:NVO) | Seeking Alpha
Novo Nordisk A/S: Mim8 phase 1 & 2 data demonstrates
A factor VIIIa–mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice - ScienceDirect
fc>2021</fc> clinical trials update: Innovations in hemophilia therapy
Novo Nordisk grows GLP-1 market share in Q2 in the US with Ozempic® and Rybelsus® - MidgardFinance.com
A factor VIIIa–mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice - ScienceDirect
Summer 2022 haemophilia trial update - European Pharmaceutical Review
Emerging drugs for hemophilia A: insights into phase II and III clinical trials
Mim8 clinical development program: an overview of the FRONTIER studies
Mim8 Well-tolerated in Early Study, Paving Way for Phase 3 Hem A Trials | Hemophilia A Clinical Trials for Mim8 Supported by Early Results | Hemophilia News Today
Mette Loftager's research works | Novo Nordisk, Copenhagen and other places
Mim8 data sees potential as once monthly treatment for haemophilia A - European Pharmaceutical Manufacturer
Pharmaceuticals | Free Full-Text | Updates on Novel Non-Replacement Drugs for Hemophilia
Bertrand Delsuc on Twitter: "Novo Nordisk R&D milestones Q3'20 $NOVO-B semaglutide ph3 initiating next year in NASH $GMAB mim8 ph1/2 in Hemophilia A readout next year https://t.co/wdlY21E8SB" / Twitter
Study Set to Assess Mim8 Therapy in People With Hemophilia A
Novo Nordisk prepares phase III trial of potential blockbuster drug — MedWatch
